Bristol-Myers Squibb (BMY) has seen a mixed bag of developments recently. BMY is upgraded to a \"Hold\" rating by Scotiabank, amidst improved profits and revenue guidance. The Pharma giant's 6-day gain streak marked a 7.7% return contrasted by an 8.9% slump YTD. Issues arose with the Milvexian trial, potentially altering BMY's cardiovascular strategy, and a late-stage trial setback for a J&J-partnered blood thinner. Despite these setbacks, BMY registered a share price uptick, sparking discussion of the company's valuation and potential investment opportunity after recent Biotech acquisitions. The company also completed €5B note offering. However, a $6.6B one-off loss called into question the quality of recent earnings. Despite these challenges, BMY's strong growth pipeline supports its high-yield dividend and Analysts assert it amongst the best 'Deep Value' stocks to buy. While BMY is challenged by some trial failures and market falls, it continues to innovate with a new AI-powered partnership for ALS Research and a $1.5 Billion deal to expand its cell therapy portfolio. Long-term value is suggested because of BMY's resilience, adapting strategy and investment potential.
Bristol-Myers Squibb BMY News Analytics from Thu, 31 Jul 2025 07:00:00 GMT to Sat, 15 Nov 2025 15:52:41 GMT -
Rating 2
- Innovation 5
- Information 8
- Rumor -3
